Transfusion and Apheresis Science最新文献_第10页

In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation 悼念里卡多-萨卡迪（Riccardo Saccardi，佛罗伦萨卡雷吉大学医院），杰出的血液病学家，通过造血干细胞移植新方法治疗自身免疫性疾病的杰出创新者

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-10 DOI: 10.1016/j.transci.2024.103985

Francesco Lanza

引用次数: 0

Editorial comment: Reflections on current position and future trends on Immunoglobulins therapy 编辑评论：对免疫球蛋白疗法现状和未来趋势的思考。

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-09 DOI: 10.1016/j.transci.2024.103986

Jerard Seghatchian

引用次数: 0

Development of Safe Blood Transfusion Self‐Efficacy Scale for nurses: Validity and reliability study 为护士编制安全输血自我效能量表：有效性和可靠性研究

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-08 DOI: 10.1016/j.transci.2024.103984

Gülsüm Dülger , Gülten Karahan Okuroglu

{"title":"Development of Safe Blood Transfusion Self‐Efficacy Scale for nurses: Validity and reliability study","authors":"Gülsüm Dülger , Gülten Karahan Okuroglu","doi":"10.1016/j.transci.2024.103984","DOIUrl":"10.1016/j.transci.2024.103984","url":null,"abstract":"<div><h3>Aim</h3><p>The aim of the study is to develop a scale to measure nurses' self-efficacy levels regarding safe blood transfusion practice.</p></div><div><h3>Methods</h3><p>This study, applied in methodological design, was conducted in a public university hospital in Istanbul between March-April 2021. The sample included 372 nurses. A draft form consisting of 75 items was prepared. Content validity, construct validity, distinctiveness, internal consistency reliability, two-half test reliability, test-retest, and item analysis methods were used to determine the psychometric properties of the scale.</p></div><div><h3>Results</h3><p>The exploratory factor analysis showed that the scale had a four-factor structure that explained 71.36 % of the total variance. The factor loads of 49 items were found to vary between 0.50 and 0.92. The item-total correlations were found to be between 0.55 and 0.92. The Cronbach's alpha value for the whole scale was 0.96.</p></div><div><h3>Conclusion</h3><p>The results of the analysis show the items constituting Safe Blood and Blood Products Transfusion Self-Efficacy Scale have validity and reliability criteria that can measure the nurses' self-efficacy levels regarding safe blood transfusion practice.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103984"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards personalized and rational use of immunoglobulins amid expanding indications and shortages 在适应症不断扩大和短缺的情况下，实现免疫球蛋白的个性化合理使用。

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-08 DOI: 10.1016/j.transci.2024.103987

Hadi Goubran , Gaafar Ragab , Jerard Seghatchian , Thierry Burnouf

{"title":"Towards personalized and rational use of immunoglobulins amid expanding indications and shortages","authors":"Hadi Goubran , Gaafar Ragab , Jerard Seghatchian , Thierry Burnouf","doi":"10.1016/j.transci.2024.103987","DOIUrl":"10.1016/j.transci.2024.103987","url":null,"abstract":"<div><p>The development of intravenous IgG (IVIG) formulations in the 1970s enabled expanded use for treating primary antibody deficiency syndromes and autoimmune conditions. Recent advancements include the use of IVIG in secondary immune deficiencies related to hematologic malignancies and stem cell transplantation, along with the newly emerging prophylactic applications following chimeric antigen receptor T-cell (CAR-T) therapies. Novel therapeutic areas such as bispecific antibodies (BsAbs) for lymphoma and myeloma have increased the use of IgG, given the associated risks of infections. Today, the concept of a rational personalized clinical use of IgG in the context of evolving clinical indications in high-income countries (HIC) is emerging, as unmet challenges in line with managing shortages due to increasing demands globally. The current work aims to review and link the indications for IgG to their characteristics and formulations, their dose, route and frequency of administrations and duration of therapy to meet the needs of individual patients. It will also explore the means to rationalize and monitor IgG use in HIC in the time of shortage, while explaining pragmatic strategies to improve supply and use in low- and middle-income countries (LMIC).</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103987"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Position paper on advancing sickle cell disease management in France by bridging the clinical practices and guidelines through expert insights 关于通过专家的真知灼见将临床实践与指导方针相结合，从而推进法国镰状细胞病管理的立场文件

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-08 DOI: 10.1016/j.transci.2024.103988

K. Benmoussa , F. Bernaudin , P. Connes , O. Héquet , L. Joseph , M. Beraud , A. Bah

{"title":"Position paper on advancing sickle cell disease management in France by bridging the clinical practices and guidelines through expert insights","authors":"K. Benmoussa , F. Bernaudin , P. Connes , O. Héquet , L. Joseph , M. Beraud , A. Bah","doi":"10.1016/j.transci.2024.103988","DOIUrl":"10.1016/j.transci.2024.103988","url":null,"abstract":"<div><p>In France, sickle cell disease (SCD) is the most common rare disease and represents the most prevalent genetic disorder, with 19,800 to 32,400 patients diagnosed in 2016 and 1:714 newborns affected in 2019. SCD is caused by a single mutation in the β-globin gene, resulting in the production of abnormal hemoglobin (called HbS), chronic hemolytic anemia, and impaired red blood cell rheology. SCD patients face several severe acute and chronic complications, including stroke, acute chest syndrome (ACS), painful vaso-occlusive crisis (VOC), organ failure, and a high risk of infections. As patients’ care pathway remains unclear in France, a roundtable advisory board meeting was organized in the country to provide insights into the management of SCD in alignment with clinical guidelines. The meeting brought together a panel of esteemed key opinion leaders (KOLs) in SCD management, encompassing both clinical practice and research. During the meeting, the KOLs discussed clinical practices and their alignment with French guidelines, identifying areas of concordance and discrepancy. They also addressed disparities in SCD clinical practices across regions and medical centers. The KOLs discussed the prophylactic and therapeutic options currently available for SCD patients in France, with a focus on transfusion therapies, especially automated red blood cell exchange (aRBCX). The results of this advisory board meeting provide a valuable platform for gathering expert perspectives on SCD management, clinical practices, guideline alignment, and the potential for contributions to guideline updates.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103988"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001599/pdfft?md5=fd5cd754b274de5308902235552624b5&pid=1-s2.0-S1473050224001599-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience 分析智利自体干细胞移植患者队列中的无排异反应结果：单中心真实世界经验。

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-02 DOI: 10.1016/j.transci.2024.103983

M Sarmiento, J Salinas, P Rojas, C Gutierrez, M Vidal, V Jara, MJ Garcia, MJ Campbell, Y Flores, V Sandoval, M Vergara, F Palacios, M Ocqueteau

{"title":"Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience","authors":"M Sarmiento, J Salinas, P Rojas, C Gutierrez, M Vidal, V Jara, MJ Garcia, MJ Campbell, Y Flores, V Sandoval, M Vergara, F Palacios, M Ocqueteau","doi":"10.1016/j.transci.2024.103983","DOIUrl":"10.1016/j.transci.2024.103983","url":null,"abstract":"<div><p>Adequate stem cell harvesting is required for autologous hematopoietic transplantation. In deficient mobilizer patients, the collection of stem cells can be challenging because of the impossibility of achieving satisfactory CD34 cell counts with GCSF + - chemotherapy. Plerixafor is a potent and expensive drug that promotes the release of stem cells from the medullary niche to the peripheral blood and allows satisfactory harvests. We performed a retrospective analysis of 370 patients with myeloma and lymphoma harvested at our institution. 99 % of patients achieved satisfactory apheresis using Plerixafor in 45 %. Satisfactory harvests were obtained in patients mobilized with GCSF or plerixafor. In patients who used plerixafor, it was necessary to perform fewer apheresis procedures (P = 0.05). In multivariate analysis, the only factor that predicted the need for plerixafor was the presence of less than 30,000 CD34 / ul on the day of apheresis (OR 0.3. p < 0.001). Since we adopted the plerixafor protocol guided by CD34 counts, the number of patients with harvest failure has decreased. In conclusion, the rational and standardized use of plerixafor favors satisfactory harvest in patients who require autologous transplantation in South-American patients.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103983"},"PeriodicalIF":1.4,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guest Editor’s Bio 特邀编辑简历

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-08-01 DOI: 10.1016/j.transci.2024.103966

Shunya Nakane

引用次数: 0

ACKR1 gene polymorphisms in Bombay blood group (Oh) individuals of Indian origin 印度裔孟买血型（Oh）个体的 ACKR1 基因多态性

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-07-25 DOI: 10.1016/j.transci.2024.103975

Roshan Shaikh , Ghosh Kanjaksha , Vasantha Kashivishwanath , Swati Kulkarni , Seema Jadhav , Harita Maru , Ajit Gorakshakar

{"title":"ACKR1 gene polymorphisms in Bombay blood group (Oh) individuals of Indian origin","authors":"Roshan Shaikh , Ghosh Kanjaksha , Vasantha Kashivishwanath , Swati Kulkarni , Seema Jadhav , Harita Maru , Ajit Gorakshakar","doi":"10.1016/j.transci.2024.103975","DOIUrl":"10.1016/j.transci.2024.103975","url":null,"abstract":"<div><h3>Background</h3><p>ACKR1 blood group genes exhibit a high degree of polymorphisms with varying allele distribution seen among different populations and ethnic groups. The study aimed to genotype ACKR1 antigens and to establish FY allele frequency among the individuals with the Bombay (Oh) blood group phenotype.</p></div><div><h3>Materials and methods</h3><p>ACKR1 phenotype and genotype frequencies were estimated on 160 individuals typed as Oh and were compared with 100 non-oh blood donors from Mumbai, India by molecularly genotyping via PCR-RFLP.</p></div><div><h3>Results</h3><p>The allelic and genotypic frequency of T(−67)C polymorphism showed the dominance of T allele and TT genotype [OR= 3.26 (0.59–17.99)] in both the study groups. The ACKR1 null (Fya-b-) phenotype was not found in the tested group. While the genotypic combination among the Oh group individuals was FYA/FYB (45.3 %), FYA/FYA (42.7 %), and FYB/FYB (12 %), in the non-Oh group donors, it was observed as FYA/FYB (53.3 %), FYA/FYA (39.1 %), and FYB/FYB (7.6 %).</p><p>The haplotype TGGGC occurred in 38.4 % of the Oh group, but in non-Oh donors, it was found to be 50.9 % [OR = 1.820 (1.196–2.771)], and the difference was statistically significant (p = 0.005). Similarly, the TGGGT haplotype was found at a frequency of 12.7 % in non-Oh donors and 27.1 % in Oh group [OR= 0.411 (0.234–0.722)] (p = 0.001).</p></div><div><h3>Conclusions</h3><p>This study shows the prevalence of ACKR1 gene polymorphisms, including weak ACKR1 antigens in Oh individuals with a high frequency of haplotype TGGGC. The present study demonstrated for the first time the genotypes FyBweak, FyAweak and Fy Aweak/FyBESon RBC membranes in Indian subjects with Oh phenotype.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103975"},"PeriodicalIF":1.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Chinese individual with DEL phenotype caused by a novel RHD allele 一名中国人患有由新型 RHD 等位基因引起的 DEL 表型。

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-07-23 DOI: 10.1016/j.transci.2024.103973

Fan Wu , Ya-dan Luo , Shuang Liang , Li-yan Sun , Tong Liu , Yan-lian Liang , Yu-qing Su

{"title":"A Chinese individual with DEL phenotype caused by a novel RHD allele","authors":"Fan Wu , Ya-dan Luo , Shuang Liang , Li-yan Sun , Tong Liu , Yan-lian Liang , Yu-qing Su","doi":"10.1016/j.transci.2024.103973","DOIUrl":"10.1016/j.transci.2024.103973","url":null,"abstract":"<div><h3>Background</h3><p>RhD variants are categorized into partial D, weak D, and DEL. The detection of DEL can only be achieved through the adsorption and elution method or molecular techniques. Here, we report a case of DEL phenotypes associated with a novel allele in a Chinese individual.</p></div><div><h3>Study design and methods</h3><p>We used serological methods such as saline, indirect anti-human globulin, and adsorption-elution. The <em>RHD</em> genotype was determined by the PCR-sequence specific primer (PCR-SSP) method as well as the Sanger dideoxy sequencing.</p></div><div><h3>Results</h3><p>RBCs of the sample were found to be DEL phenotype by serological testing, with negative reactions in the saline and indirect anti-human globulin tests while positive reactions by the absorption–elution method. The genotyping results revealed a hemizygous (<em>RHD</em><sup>c .1127 T>G</sup>/<em>RHD</em>-). The novel allele sequence has been submitted to GenBank (Accession number: OR608456).</p></div><div><h3>Conclusion</h3><p>Our study demonstrates a case of a Chinese individual with DEL phenotype caused by a novel allele <em>RHD</em> c .1127 T > G. It expands the database of the DEL variant.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103973"},"PeriodicalIF":1.4,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast milk induced immune haemolytic disease of newborn due to anti-c: A case report 抗生素引起的母乳性新生儿免疫性溶血病：病例报告

IF 1.4 4区医学

Transfusion and Apheresis Science Pub Date : 2024-07-22 DOI: 10.1016/j.transci.2024.103974

Aarushi Sahni , Vasanthakumar Karumannan , Lakhvinder Singh , Richa Jain , Ratti Ram Sharma

引用次数: 0